Which P2Y12 inhibitor is available in an intravenous formulation for rapid platelet inhibition during PCI?
Show answer and explanation
Correct answer: Cangrelor
Cangrelor is an intravenous, reversible P2Y12 antagonist with an extremely rapid onset and a half-life of only 3-6 minutes. This allows for nearly immediate platelet inhibition and rapid recovery of function after the infusion is stopped.
Keep practicing
More Antiplatelet Drugs questions
- Ticlopidine is rarely used today primarily due to the risk of which hematologic toxicity?
- Which of the following drugs is a non-peptide, small molecule mimetic that reversibly inhibits the GP IIb/IIIa receptor?
- Platelet activation involves the release of granules containing which substances that further amplify aggregation?
- Why does low-dose Aspirin (81mg) exhibit selectivity for inhibiting platelet COX-1 over systemic COX-2?
- The use of Proton Pump Inhibitors (PPIs) like Omeprazole with Clopidogrel is controversial because:
- What is the primary mechanism of action of Aspirin in inhibiting platelet aggregation?